Inhibrx Reports Tomorrow With Analysts Bracing for Wider Loss

Inhibrx Biosciences (INBX) is scheduled to report second-quarter 2026 earnings on August 12, 2026, with the consensus estimate calling for a loss of $2.50 per share. The central question for investors is whether the clinical-stage biopharmaceutical company can continue narrowing its losses as it advances its pipeline of novel therapeutics, or if development costs will weigh more heavily than expected. With analyst price targets implying substantial upside and the stock trading near $92.38, this report will test whether recent momentum can be sustained.

Part 1: Earnings Preview

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel protein therapeutics for oncology and rare diseases, utilizing its proprietary single-domain antibody (sdAb) platform. The company's pipeline includes multiple candidates targeting solid tumors and orphan indications, making it a high-risk, high-reward play in the biotech sector.

Inhibrx is expected to report Q2 2026 earnings on August 12, 2026, with analysts projecting a loss of $2.50 per share. The company most recently reported Q1 2026 earnings of -$2.15 per share, which beat the consensus estimate of -$2.37 by $0.22. Compared to the same quarter last year (Q2 2025), when INBX reported a loss of -$1.85 per share, the current estimate of -$2.50 represents a 35% deterioration year-over-year, reflecting increased R&D spending as clinical programs advance.

Three key themes define this earnings story:

Clinical Pipeline Progress: Investors will scrutinize updates on INBX-106 (alpha-CTLA-4 probody) and INBX-109 (OX40 agonist), particularly any data readouts or enrollment milestones that could validate the company's differentiated approach to immuno-oncology.

Cash Runway and Burn Rate: With losses expected to widen, the quarterly cash burn rate and remaining runway will be critical. Any commentary on capital allocation, potential partnerships, or financing plans will move the stock.

Regulatory and Development Timelines: Updates on IND filings, trial initiations, or FDA interactions for pipeline candidates will provide visibility into when the company might reach value-inflection points.

Analyst commentary ahead of the release has been cautiously optimistic, with two Strong Buy ratings balanced by two Hold ratings. The consensus price target of $277.50 implies substantial upside, but analysts acknowledge the binary nature of clinical-stage biotech and the need for continued execution on development milestones.

Part 2: Historical Earnings Performance

Inhibrx Biosciences has demonstrated a mixed but generally positive track record of beating earnings estimates over the past four quarters. In Q2 2025, the company reported a loss of -$1.85 per share against an estimate of -$2.92, delivering a substantial 36.64% beat. The most recent quarter (Q1 2026) saw another beat, with reported EPS of -$2.15 versus the estimate of -$2.37, a 9.28% positive surprise.

However, Q3 2025 and Q4 2025 lacked consensus estimates for comparison, making it difficult to assess performance during those periods. The available data suggests that when estimates are available, INBX has consistently outperformed expectations by managing costs more effectively than analysts anticipated. This pattern of positive surprises could set a favorable precedent heading into the Q2 2026 report, though the widening year-over-year loss estimate suggests analysts are bracing for higher development expenses as clinical programs mature.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Inhibrx Biosciences typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around earnings shows significant volatility, with the stock exhibiting an average absolute Day 0 move of 4.17% and a Day +1 move of 3.91%. The Day 0 range averages 7.34%, while Day +1 ranges average 9.67%, indicating substantial intraday swings as investors digest results.

The most dramatic reaction came in May 2026, when the stock declined 6.47% on Day +1 with a range of 14.13%, despite beating estimates. Conversely, November 2025 saw a 6.04% Day 0 gain followed by a 2.25% Day +1 decline, illustrating how initial enthusiasm can reverse. The pattern suggests INBX is prone to sharp moves in both directions, with Day +1 often bringing wider ranges as the market fully processes clinical updates and guidance. Investors should prepare for potential swings exceeding 10% in either direction based on the historical average range.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 6.99% for the upcoming earnings release, which is moderately higher than the historical average Day 0 move of 4.17% but below the average Day +1 move of 3.91% when combined with Day 0 volatility. This suggests options traders are anticipating a meaningful reaction, though not as extreme as some past episodes like the 14.13% Day +1 range seen in May 2026.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on Inhibrx Biosciences, with a consensus rating of 4.00 (Buy) and an average price target of $277.50. The current breakdown shows 2 Strong Buy ratings and 2 Hold ratings, with no Sell or Strong Sell recommendations. Price targets range from a low of $230.00 to a high of $325.00, reflecting divergent views on the company's pipeline potential.

Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.00. This stability suggests analysts are waiting for concrete clinical data or development milestones before adjusting their views.

From the current price of $92.38, the consensus target of $277.50 implies potential upside of approximately 200%, underscoring the high-risk, high-reward nature of this clinical-stage biotech. The wide target range reflects uncertainty around clinical trial outcomes and regulatory timelines, with bulls betting on successful pipeline execution and bears concerned about cash burn and binary trial risks.

Part 4: Technical Picture

Inhibrx Biosciences enters earnings with a mixed technical picture that has shifted notably in recent weeks. The Barchart Technical Opinion currently shows a 16% Buy signal, a significant improvement from last week's 40% Sell signal, though it remains below last month's 40% Buy reading. This volatility in the signal reflects the stock's recent price action and uncertain near-term direction.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum faces headwinds despite recent gains
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive
• Long-term (50% Buy): Moderate buy signal reflects a positive longer-term trajectory as the stock holds above key moving averages

Trend Characteristics: The trend is characterized by Minimum strength and the Weakest direction, suggesting the stock lacks conviction heading into earnings and could be vulnerable to sharp moves in either direction based on results.

The stock is currently trading at $92.38, positioned above its 5-day ($88.77), 10-day ($85.61), 20-day ($85.50), 50-day ($90.71), and 200-day ($85.58) moving averages, but below its 100-day moving average ($93.63). This configuration shows the stock has recovered from recent lows and is trading above most key support levels, though it faces resistance near the 100-day average.

The technical setup heading into earnings is cautiously supportive but fragile. While the stock has reclaimed most major moving averages, the weak trend characteristics and conflicting timeframe signals suggest limited conviction. The 100-day moving average at $93.63 represents immediate overhead resistance, while the 50-day at $90.71 provides nearby support. Given the historical volatility around earnings and the current lack of directional strength, traders should expect the stock to be highly reactive to any surprises in the report or clinical updates. The technical picture suggests INBX is coiled for a significant move, but the direction will depend entirely on the quality of results and management commentary.